Home
Clinical Trials
Efficacy and Safety of Sacubi...

Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC

Last Updated: 2025-11-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

918 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-12-10

Study Completion Date

2025-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the effect of sacubitril/valsartan 200 mg BID compared with enalapril 10 mg BID, in addition to conventional heart failure (HF) treatment, in improving a hierarchical composite of cardiovascular (CV) events (i.e. CV death or the occurrence of first HF hospitalization) and causing a greater reduction in n terminal prohormone of brain natriuretic peptide (NT-proBNP, at Week 12 from Baseline) in participants with HF with reduced ejection fraction (HFrEF) caused by CCC.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF.

NCT04853758

Chagas Cardiomyopathy

RECRUITING PHASE3

A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy

NCT01557140

Chagas Cardiomyopathy Heart Failure Dilated Cardiomyopathy

COMPLETED PHASE4

The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients

NCT03300427

Heart Failure

COMPLETED PHASE4

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

NCT03988634

Heart Failure With Preserved Ejection Fraction (HFpEF)

COMPLETED PHASE3

Chagas Cardiomyopathy Bisoprolol Intervention Study: Charity

NCT00323973

Chagas Cardiomyopathy Chronic Heart Failure

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chagas Disease Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This is a Phase 4, multinational, multicenter, parallel-group, prospective, randomized, open-label, blinded-endpoint adjudication, active-controlled study to demonstrate superiority of sacubitril/valsartan over enalapril in improving a composite of CV events (CV death or first HF hospitalization), or in causing greater reduction or lesser increase in NT-proBNP levels at Week 12 in participants with HFrEF caused by CCC.

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Endpoint Adjudication Committee will be blinded to treatment allocation.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sacubitril/valsartan

Sacubitril/valsartan 200 mg b.i.d.

Following randomization, patients will receive sacubitril/valsartan in titrated doses from level 1 up to level 3 (50, 100 and 200 mg twice daily).

Participants taking ACEIs who are randomized to sacubitril/valsartan will do a 36-hour ACEI washout before they start taking the study drug

Sacubitril/valsartan in dose levels of 50 mg, 100 mg, and 200 mg are equivalent to sacubitril/valsartan 24/26 mg, 49/51 mg and 97/103 mg, respectively

Group Type EXPERIMENTAL

Sacubitril/valsartan

Intervention Type DRUG

50 (24/26) mg, 100 (49/51) mg and 200 (97/103) mg will be available for dose adjustments.

Enalapril

Enalapril 10 mg b.i.d.

Following randomization, patients will receive the enalapril in titrated doses from level 1 up to level 3 (2.5, 5 and 10 mg twice daily).

Group Type ACTIVE_COMPARATOR

Enalapril

Intervention Type DRUG

5 mg and 10 mg will be available for dose adjustments.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sacubitril/valsartan

50 (24/26) mg, 100 (49/51) mg and 200 (97/103) mg will be available for dose adjustments.

Intervention Type DRUG

Enalapril

5 mg and 10 mg will be available for dose adjustments.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LCZ696; Entresto; Vymada Renitec

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female ≥ 18 years of age
* Diagnosis of NYHA Class II-IV HFrEF established by:

1. LVEF ≤ 40% within 12 months prior to Visit 1 made by any local measurement using echocardiography, multiple gated acquisition scan (MUGA), computerized tomography (CT) scanning, magnetic resonance imaging (MRI), or ventricular angiography, provided no subsequent measurement above 40% AND
2. NT-proBNP ≥ 600 pg/mL (or BNP ≥ 150 pg/mL) at Visit 1 OR
3. NT-proBNP ≥ 400 pg/mL (or BNP ≥ 100 pg/mL) at Visit 1 and a hospitalization for HF within the last 12 months
* Chagas' disease diagnosis confirmed by at least two different serological tests for anti-Trypanosoma cruzi based on different principles or with different antigenic preparations, such as: enzyme-linked immunosorbent assay \[ELISA\], indirect immunofluorescence \[IFI\], indirect hemagglutination \[IHA\], western blot (WB), chemiluminescent immunoassay (CLIA). If documented history is not available, the tests may be performed during the screening

Exclusion Criteria

* Patients with history of suspected or proven angioedema or unable to tolerate ACEIs, ARBs or ARNI (e.g., due to cough, hypotension, renal dysfunction, hyperkalemia)
* Use of sacubitril/valsartan in the past 3 months
* Patients requiring continuous intravenous inotropic therapy or with indication of advanced support intervention for HF:

1. already on list for a heart transplantation
2. with current indication of left ventricular assist device, or cardiac resynchronization therapy (CRT)
* Systemic systolic blood pressure lower than 95 mmHg or symptomatic hypotension
* Serum potassium \> 5.2 mmol/L
* Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m2 of body surface area
* Severe gastrointestinal form of chronic Chagas' disease (demonstrated megaesophagus and/or important megacolon, e.g.: with compromised oral intake or surgical indication).
* Clinical conditions or systemic diseases limiting proper patient participation
* Pregnant or nursing women or women of child-bearing potential unless they are using highly effective methods of contraception
* Presence of other cardiac conditions:

1. Previous cardiac surgery
2. Heart failure where, in the Investigator's judgement, there is a possible alternative primary etiology e.g., due to coronary artery disease, valve disease, congenital heart disease or other causes.
3. Untreated arrhythmia or serious conduction disease e.g., bradyarrhythmias, atrial fibrillation with rapid ventricular response, second or third degree atrioventricular block, etc.
4. Primary uncorrected valvar pathology like moderate to severe aortic stenosis, mitral stenosis and primary mitral regurgitation
5. Planned organ transplantation (or in listing for transplantation), planned cardiac or other major surgery (including ventricular assist device implantation)
* History of malignancy of any organ system within the past 5 years.
* Current confirmed COVID19 infection
* Past COVID19 infection with persistent symptom burden suspected due to COVID19 (persistent symptoms may include, but are not limited to, continued cough, breathing difficulty, muscle/joint aches, and gastrointestinal symptoms from the time of COVID19 infection onward)

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers